{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:24:02Z","timestamp":1648567442964},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1684\/bdc.2012.1579","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"563-570","source":"Crossref","is-referenced-by-count":1,"title":["Traitements de l\u2019an\u00e9mie par carence martiale en oncologie"],"prefix":"10.1016","volume":"99","author":[{"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Launay-Vacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2012.1579_bib0005","first-page":"120","article-title":"Living with cancer-related anaemia. -What is the reality?","volume":"1","author":"Foubert","year":"2007","journal-title":"Eur Oncol Dis"},{"key":"10.1684\/bdc.2012.1579_bib0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejon.2010.01.003","article-title":"Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy","volume":"14","author":"Akin","year":"2010","journal-title":"Eur J Oncol Nurs"},{"key":"10.1684\/bdc.2012.1579_bib0015","first-page":"S128","article-title":"Anemia in cancer patients before treatment","volume":"90","author":"Auclerc","year":"2003","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2012.1579_bib0020","first-page":"112","article-title":"Fatigue et an\u00e9mie chez le patient canc\u00e9reux","volume":"123","author":"Longueville","year":"2004","journal-title":"Louvain Med"},{"key":"10.1684\/bdc.2012.1579_bib0025","first-page":"439","article-title":"An\u00e9mie chez les patients atteints de cancer pulmonaire","volume":"92","author":"M\u00e9ric","year":"2005","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2012.1579_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0035","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"American Society of Clinical Oncology\/American Society of Hematology Clinical Practice Guideline Update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"28","author":"Rizzo","year":"2010","journal-title":"Jco"},{"key":"10.1684\/bdc.2012.1579_bib0040","unstructured":"National Comprehensive Cancer Network (NCCN) 2011. Practice guidelines in oncology : Cancer and chemotherapy induced an\u00e9mia (version 2.2011). recommandations t\u00e9l\u00e9chargeables sur le site www.nccn.org"},{"key":"10.1684\/bdc.2012.1579_bib0045","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1684\/bdc.2012.1579_bib0050","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective Survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2012.1579_bib0055","first-page":"641","article-title":"Serum ferritin levels and transferrin saturation in men with prostate cancer","volume":"96","author":"Kuvibidila","year":"2004","journal-title":"J Natl Med Assoc"},{"key":"10.1684\/bdc.2012.1579_bib0060","unstructured":"Ludwig EHA. 2010 : abstract 1816 et EHA 2011 : abstract 982."},{"key":"10.1684\/bdc.2012.1579_bib0065","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron. Supplementation in patients with chemotherapy related an\u00e9mia without deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0075","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1200\/JCO.2011.35.3219","article-title":"Too-low iron. doses and too many dropouts in negative iron trial?","volume":"29","author":"Aapro","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0080","unstructured":"Ludwig H et al. MASCC 2011 ; abstract 256."},{"key":"10.1684\/bdc.2012.1579_bib0085","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron. Optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related an\u00e9mia : a multicenter, open label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron. Or no iron. In anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2012.1579_bib0095","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron. To epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies : a randomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2012.1579_bib0105","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2012.1579_bib0115","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2012.1579_bib0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2012.1579_bib0125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0130","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0135","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0140","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2012.1579_bib0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.13-S3-33","article-title":"September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents","volume":"13","author":"Aapro","year":"2008","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2012.1579_bib0150","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron. In patients with chemotherapy-induced an\u00e9mia","volume":"26","author":"Bastit","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0155","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ygyno.2009.12.004","article-title":"Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy","volume":"116","author":"Dangsuwan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2006.11.014","article-title":"Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy","volume":"105","author":"Kim","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3747\/co.2007.149","article-title":"Canadian supportive care recommendations for the management of anemia in patients with cancer","volume":"14","author":"Mikhael","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1684\/bdc.2012.1579_bib0170","first-page":"11","article-title":"The pharmacology and safety profile of ferric carboxymaltose (Ferinject\u00ae) : structure\/reactivity relationship of iron. Preparations","volume":"23","author":"Geisser","year":"2009","journal-title":"Port J Nephrol Hypert"},{"key":"10.1684\/bdc.2012.1579_bib0175","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques produit Ferinject\u00ae"},{"key":"10.1684\/bdc.2012.1579_bib0180","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2141.2003.03590.x","article-title":"Pharmacokinetics and red cell utilization of 52 Fe\/59 Fe-labelled iron. Polymaltose in anaemic patients using positron \u00e9mission tomography","volume":"120","author":"Beshara","year":"2003","journal-title":"Br J Haematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115304495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115304495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:33:08Z","timestamp":1602491588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115304495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0007455115304495"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2012.1579","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}